No Data
Promising Interim Clinical Trial Results Bolster Confidence in Lexeo Therapeutics' Gene Therapy Potential
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Solid Biosciences (SLDB) and Lexeo Therapeutics, Inc. (LXEO)
Friedreich's Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key Companies - Retrotope, PTC Therapeutics, Minoryx Therapeutics, Biogen, Lexeo Therapeutics, Larimar Therapeutics
HC Wainwright & Co. Reiterates Buy on Lexeo Therapeutics, Maintains $22 Price Target
H.C. Wainwright Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $22
H.C. Wainwright analyst Mitchell Kapoor maintains $Lexeo Therapeutics(LXEO.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 4
Analysts Are Bullish on These Healthcare Stocks: Instil Bio (TIL), Lexeo Therapeutics, Inc. (LXEO)
No Data